NCT06908304 2026-01-12
A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC
Maia Biotechnology
Phase 3 Recruiting
Maia Biotechnology
Sinocelltech Ltd.
Takeda
Celgene
Sanofi
Guangdong Association of Clinical Trials
Pfizer
Pfizer